Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon.
   Int J Clin Oncol, 10(2): 144-7. [Abstract] [Full-text]
2. Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes.
   Int J Clin Oncol, 10(2): 86-96. [Abstract] [Full-text]
3. A clinicopathological investigation of "tumor nodules" in colorectal cancer.
   Surg Today, 35(5): 377-84. [Abstract] [Full-text]
4. The MAPK signalling pathways and colorectal cancer.
   Lancet Oncol, 6(5): 322-7. [Abstract] [Full-text]
5. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
   Lancet Oncol, 6(5): 279-86. [Abstract] [Full-text]
6. Alphavbeta5-integrins mediate early steps of metastasis formation.
   Eur J Cancer, 41(7): 1065-72. [Abstract] [Full-text]
7. Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma.
   Eur J Cancer, 41(7): 1058-64. [Abstract] [Full-text]
8. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore.
   Eur J Cancer, 41(7): 1037-44. [Abstract] [Full-text]
9. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer.
   Am J Surg, 189(5): 512-7; discussion 517. [Abstract] [Full-text]
10. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation).
    Ann Surg Oncol, 12(4): 298-302. [Abstract] [Full-text]
11. Arteriolovenular shunting critically determines shutdown of microcirculation upon cryotherapy in tumor-bearing rat liver.
    Ann Surg Oncol, 12(4): 303-12. [Abstract] [Full-text]
12. Effect of supervised surgical training on outcomes after resection of colorectal cancer.
    Br J Surg, 92(5): 631-6. [Abstract] [Full-text]
13. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Oncology, 68(1): 58-63. [Abstract] [Full-text]
14. Influence of various cytokines on adhesion and migration of the colorectal adenocarcinoma cell line HRT-18.
    Oncology, 68(1): 33-9. [Abstract] [Full-text]
15. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
    Mol Carcinog, 43(1): 13-7. [Abstract] [Full-text]
16. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.
    Virchows Arch, 446(4): 411-5. [Abstract] [Full-text]
17. Doppler assessment after right hepatectomy confirms the need to fix the remnant left liver in the anatomical position.
    Br J Surg, 92(5): 592-5. [Abstract] [Full-text]
18. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer.
    Br J Surg, 92(5): 615-23. [Abstract] [Full-text]
19. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
    Br J Surg, 92(5): 605-14. [Abstract] [Full-text]
20. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis.
    Support Care Cancer, 13(5): 318-24. [Abstract] [Full-text]
21. Vanadium inhibits DNA-protein cross-links and ameliorates surface level changes of aberrant crypt foci during 1,2-dimethylhydrazine induced rat colon carcinogenesis.
    Cell Biol Toxicol, 21(1): 41-52. [Abstract] [Full-text]
22. Colorectal cancer screening in average risk individuals.
    Cancer Causes Control, 16(2): 171-88. [Abstract] [Full-text]
23. What do cancer survivors believe causes cancer? (United States).
    Cancer Causes Control, 16(2): 115-23. [Abstract] [Full-text]
24. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
    Invest New Drugs, 23(3): 243-51. [Abstract] [Full-text]
25. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
    Cancer Res, 65(9): 3942-9. [Abstract] [Full-text]
26. Elucidation of thioredoxin as a molecular target for antitumor quinols.
    Cancer Res, 65(9): 3911-9. [Abstract] [Full-text]
27. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors.
    Cancer Res, 65(9): 3811-4. [Abstract] [Full-text]
28. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
    Cancer Res, 65(9): 3716-25. [Abstract] [Full-text]
29. Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice.
    Clin Cancer Res, 11(9): 3574-8. [Abstract] [Full-text]
30. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
    Clin Cancer Res, 11(9): 3494-502. [Abstract] [Full-text]
31. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
    Clin Cancer Res, 11(9): 3363-8. [Abstract] [Full-text]
32. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
    Clin Cancer Res, 11(9): 3296-302. [Abstract] [Full-text]
33. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance.
    Clin Cancer Res, 11(9): 3288-95. [Abstract] [Full-text]
34. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients.
    Clin Cancer Res, 11(9): 3274-9. [Abstract] [Full-text]
35. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
    Mol Cell Endocrinol, 235(1): 21-9. [Abstract] [Full-text]
36. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women.
    J Natl Cancer Inst, 97(9): 684-92. [Abstract] [Full-text]
37. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases.
    Br J Cancer, 92(9): 1746-53. [Abstract] [Full-text]
38. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
    Br J Cancer, 92(9): 1655-62. [Abstract] [Full-text]
39. No association between fruit or vegetable consumption and the risk of colorectal cancer in Japan.
    Br J Cancer, 92(9): 1782-4. [Abstract] [Full-text]
40. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women.
    Br J Cancer, 92(9): 1803-7. [Abstract] [Full-text]
41. Factors influencing sexual function in patients with rectal cancer.
    Int J Impot Res, 17(3): 231-8. [Abstract] [Full-text]
42. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    N Engl J Med, 352(18): 1851-60. [Abstract] [Full-text]
43. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas.
    Cancer, 103(10): 2163-70. [Abstract] [Full-text]
44. Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumor location.
    Cancer, 103(10): 2023-9. [Abstract] [Full-text]
45. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Cancer Chemother Pharmacol, 56(1): 10-4. [Abstract] [Full-text]
46. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial.
    Dis Colon Rectum, 48(3): 504-9. [Abstract] [Full-text]
47. Evaluation of P-POSSUM in surgery for obstructing colorectal cancer and correlation of the predicted mortality with different surgical options.
    Dis Colon Rectum, 48(3): 493-8. [Abstract] [Full-text]
48. Metastatic testicular carcinoma from the colon with clinical, immunophenotypical, and molecular characterization: report of a case.
    Dis Colon Rectum, 48(3): 582-5. [Abstract] [Full-text]
49. Ten-year historic cohort of quality of life and sexuality in patients with rectal cancer.
    Dis Colon Rectum, 48(3): 483-92. [Abstract] [Full-text]
50. Immediate radical resection after local excision of rectal cancer: an oncologic compromise?
    Dis Colon Rectum, 48(3): 429-37. [Abstract] [Full-text]
51. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach.
    Dis Colon Rectum, 48(3): 444-50. [Abstract] [Full-text]
52. Investigation of APC mutations in a Turkish familial adenomatous polyposis family by heterodublex analysis.
    Dis Colon Rectum, 48(3): 567-71. [Abstract] [Full-text]
53. Primary perineal wound closure after preoperative radiotherapy and abdominoperineal resection has a high incidence of wound failure.
    Dis Colon Rectum, 48(3): 438-43. [Abstract] [Full-text]
54. Sutured perineal omentoplasty after abdominoperineal resection for adenocarcinoma of the lower rectum.
    Dis Colon Rectum, 48(3): 476-81; discussion 481-2. [Abstract] [Full-text]
55. Use of Malone antegrade continence enema in patients with perineal colostomy after rectal resection.
    Dis Colon Rectum, 48(3): 499-503. [Abstract] [Full-text]
56. The influence of specific luminal factors on the colonic epithelium: high-dose butyrate and physical changes suppress early carcinogenic events in rats.
    Dis Colon Rectum, 48(3): 549-59. [Abstract] [Full-text]
57. Expression of granulocyte colony stimulating factor receptor in human colorectal cancer.
    Postgrad Med J, 81(955): 333-7. [Abstract] [Full-text]
58. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
    Clin Ther, 27(3): 327-35. [Abstract] [Full-text]
59. Testicular dose and hormonal changes after radiotherapy of rectal cancer.
    Radiother Oncol, 75(1): 83-8. [Abstract] [Full-text]
60. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells.
    J Biol Chem, 280(19): 19027-35. [Abstract] [Full-text]
61. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues.
    J Pathol, 206(2): 233-41. [Abstract] [Full-text]
62. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    J Pathol, 206(2): 198-204. [Abstract] [Full-text]
63. Effects of Brussels sprout juice on the cell cycle and adhesion of human colorectal carcinoma cells (HT29) in vitro.
    J Agric Food Chem, 53(10): 3895-901. [Abstract] [Full-text]
64. The place of the posterior surgical approach for lesions of the rectum.
    Dig Surg, 22(1): 86-90. [Abstract] [Full-text]
65. Rectal cancer: the role of radiotherapy.
    Dig Surg, 22(1): 41-8; discussion 49. [Abstract] [Full-text]
66. Laparoscopy for colorectal malignancy.
    Dig Surg, 22(1): 34-40. [Abstract] [Full-text]
67. Mouse models of colorectal cancer and liver metastases.
    Dig Surg, 22(1): 16-25. [Abstract] [Full-text]
68. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group.
    Gut, 54(6): 807-13. [Abstract] [Full-text]
69. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Gut, 54(6): 803-6. [Abstract] [Full-text]
70. O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions.
    Gut, 54(6): 797-802. [Abstract] [Full-text]
71. CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer.
    Dig Liver Dis, 37(3): 170-5. [Abstract] [Full-text]
72. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas.
    Dig Liver Dis, 37(3): 162-9. [Abstract] [Full-text]
73. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma.
    Hum Pathol, 36(4): 364-71. [Abstract] [Full-text]
74. Transient upregulation of GRP and its receptor critically regulate colon cancer cell motility during remodeling.
    Am J Physiol Gastrointest Liver Physiol, 288(6): G1274-82. [Abstract] [Full-text]
75. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(2): 479-85. [Abstract] [Full-text]
76. Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin.
    Cancer Lett, 223(1): 159-67. [Abstract] [Full-text]
77. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI).
    Cancer Lett, 223(1): 137-42. [Abstract] [Full-text]
78. Associated nutritional risk of breast and colon cancers: a population-based case-control study in Montreal, Canada.
    Cancer Lett, 223(1): 85-91. [Abstract] [Full-text]
79. TGF-beta signaling in colon cancer cells.
    World J Surg, 29(3): 306-11. [Abstract] [Full-text]
80. Effects of irradiation combined with cis-diamminedichloroplatinum (CDDP) suppository in rabbit VX2 rectal tumors.
    World J Surg, 29(3): 388-95. [Abstract] [Full-text]
81. Hepatic tumor growth: target for angiogenesis inhibition?
    World J Surg, 29(3): 287-92. [Abstract] [Full-text]
82. Colorectal cancer screening among African-American and white male veterans.
    Am J Prev Med, 28(5): 479-82. [Abstract] [Full-text]
83. Colorectal cancer screening attitudes and practices preferences for decision making.
    Am J Prev Med, 28(5): 439-46. [Abstract] [Full-text]
84. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.
    Lancet, 365(9472): 1718-26. [Abstract] [Full-text]
85. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.
    Clin Cancer Res, 11(10): 3758-65. [Abstract] [Full-text]
86. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    Clin Cancer Res, 11(10): 3705-13. [Abstract] [Full-text]
87. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance.
    Clin Cancer Res, 11(10): 3642-6. [Abstract] [Full-text]
88. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
    Clin Cancer Res, 11(10): 3633-41. [Abstract] [Full-text]
89. A rare transporter associated with antigen processing polymorphism overpresented in HLAlow colon cancer reveals the functional significance of the signature domain in antigen processing.
    Clin Cancer Res, 11(10): 3614-23. [Abstract] [Full-text]
90. Overexpression of hRFI (human ring finger homologous to inhibitor of apoptosis protein type) inhibits death receptor-mediated apoptosis in colorectal cancer cells.
    Mol Cancer Ther, 4(5): 743-50. [Abstract] [Full-text]
91. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3).
    Mol Cancer Ther, 4(5): 693-703. [Abstract] [Full-text]
92. Predictive neural networks for gene expression data analysis.
    Neural Netw, 18(3): 297-306. [Abstract] [Full-text]
93. Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture--regulation of cathepsin B expression and invasiveness.
    Cancer Lett, 223(2): 313-22. [Abstract] [Full-text]
94. A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC family from Southern Italy.
    Cancer Lett, 223(2): 285-91. [Abstract] [Full-text]
95. Polyethylene glycol reduces inflammation and aberrant crypt foci in carcinogen-initiated rats.
    Cancer Lett, 223(2): 203-9. [Abstract] [Full-text]
96. A comparison in five European Centres of case mix, clinical management and outcomes following either conventional or fast-track perioperative care in colorectal surgery.
    Clin Nutr, 24(3): 455-61. [Abstract] [Full-text]
97. Local excision of rectal cancer: review of literature.
    Dig Surg, 22(1): 6-15. [Abstract] [Full-text]
98. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices.
    Bioinformatics, 21(10): 2301-8. [Abstract] [Full-text]
99. Familial risks for colorectal cancer show evidence on recessive inheritance.
    Int J Cancer, 115(5): 835-8. [Abstract] [Full-text]
100. Dietary patterns and subsequent colorectal cancer risk by subsite: a prospective cohort study.
     Int J Cancer, 115(5): 790-8. [Abstract] [Full-text]
101. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma.
     Int J Cancer, 115(5): 673-7. [Abstract] [Full-text]
102. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
     Int J Cancer, 115(5): 783-9. [Abstract] [Full-text]
103. CpG island methylation in aberrant crypt foci and cancers from the same patients.
     Int J Cancer, 115(5): 747-51. [Abstract] [Full-text]
104. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel.
     Cancer Res, 65(10): 4401-7. [Abstract] [Full-text]
105. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis.
     Cancer Res, 65(10): 4261-72. [Abstract] [Full-text]
106. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis.
     Cancer Res, 65(10): 4228-37. [Abstract] [Full-text]
107. Mesalazine improves replication fidelity in cultured colorectal cells.
     Cancer Res, 65(10): 3993-7. [Abstract] [Full-text]
108. Laparoscopically assisted resection of an ascending colon lipoma causing intermittent intussusception.
     J Laparoendosc Adv Surg Tech A, 15(2): 173-5. [Abstract] [Full-text]
109. Social and geographic disparities in access to reference care site for patients with colorectal cancer in France.
     Br J Cancer, 92(10): 1842-5. [Abstract] [Full-text]
110. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
     Br J Cancer, 92(10): 1846-9. [Abstract] [Full-text]
111. Mutation analysis of the MYH gene in an Australian series of colorectal polyposis patients with or without germline APC mutations.
     Int J Cancer, 116(1): 73-7. [Abstract] [Full-text]
112. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells.
     Int J Cancer, 116(1): 52-61. [Abstract] [Full-text]
113. Mucin-depleted foci have beta-catenin gene mutations, altered expression of its protein, and are dose- and time-dependent in the colon of 1,2-dimethylhydrazine-treated rats.
     Int J Cancer, 116(1): 9-15. [Abstract] [Full-text]
114. Development of the vasculature in "pushing-type" liver metastases of an experimental colorectal cancer.
     Int J Cancer, 115(6): 893-902. [Abstract] [Full-text]
115. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms.
     Int J Cancer, 115(6): 943-50. [Abstract] [Full-text]
116. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.
     Int J Cancer, 115(6): 924-9. [Abstract] [Full-text]
117. Colonoscopic screening of average-risk women for colorectal neoplasia.
     N Engl J Med, 352(20): 2061-8. [Abstract] [Full-text]
118. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth.
     Differentiation, 73(4): 142-53. [Abstract] [Full-text]
119. Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist.
     Cancer Sci, 96(5): 260-4. [Abstract] [Full-text]
120. Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
     Chin J Dig Dis, 6(2): 82-6. [Abstract] [Full-text]
121. Quality of life, functional outcome, and complications of coloplasty pouch after low anterior resection.
     Dis Colon Rectum, 48(4): 735-43. [Abstract] [Full-text]
122. Recurrence after transanal excision of T1 rectal cancer: should we be concerned?
     Dis Colon Rectum, 48(4): 711-9; discussion 719-21. [Abstract] [Full-text]
123. Using the gastroscope for incomplete colonoscopy.
     Dis Colon Rectum, 48(4): 851-4. [Abstract] [Full-text]
124. Eight years experience of high-powered endoscopic diode laser therapy for palliation of colorectal carcinoma.
     Dis Colon Rectum, 48(4): 845-50. [Abstract] [Full-text]
125. Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis.
     Dis Colon Rectum, 48(4): 816-23. [Abstract] [Full-text]
126. How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?
     Dis Colon Rectum, 48(4): 722-8. [Abstract] [Full-text]
127. Surveillance-detected hepatic metastases from colorectal cancer had a survival advantage in seven-year follow-up.
     Dis Colon Rectum, 48(4): 744-8. [Abstract] [Full-text]
128. Colonic J-pouch-anal anastomosis for rectal cancer: a prospective, randomized study comparing handsewn vs. stapled anastomosis.
     Dis Colon Rectum, 48(4): 729-34. [Abstract] [Full-text]
129. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
     J Clin Oncol, 23(15): 3545-51. [Abstract] [Full-text]
130. Molecular determinants of cetuximab efficacy.
     J Clin Oncol, 23(15): 3536-44. [Abstract] [Full-text]
131. Molecular staging for survival prediction of colorectal cancer patients.
     J Clin Oncol, 23(15): 3526-35. [Abstract] [Full-text]
132. Clinical value of mitochondrial mutations in colorectal cancer.
     J Clin Oncol, 23(15): 3517-25. [Abstract] [Full-text]
133. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
     J Clin Oncol, 23(15): 3502-8. [Abstract] [Full-text]
134. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point.
     J Clin Oncol, 23(15): 3475-9. [Abstract] [Full-text]
135. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
     Ann Oncol, 16(6): 869-77. [Abstract] [Full-text]
136. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
     Ann Oncol, 16(6): 878-86. [Abstract] [Full-text]
137. Tumour budding detected by laminin-5 {gamma}2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer.
     Ann Oncol, 16(6): 893-8. [Abstract] [Full-text]
138. Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line.
     Mol Carcinog, 43(2): 65-74. [Abstract] [Full-text]
139. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study.
     Mod Pathol, 18(6): 816-21. [Abstract] [Full-text]
140. Morphology of colorectal lymphoid aggregates in cancer, diverticular and inflammatory bowel diseases.
     Mod Pathol, 18(5): 681-5. [Abstract] [Full-text]
141. Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly.
     Surg Today, 35(6): 442-5. [Abstract] [Full-text]
142. Sex differences in hospital readmission among colorectal cancer patients.
     J Epidemiol Community Health, 59(6): 506-11. [Abstract] [Full-text]
143. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.
     Eur J Cancer, 41(8): 1195-202. [Abstract] [Full-text]
144. Effect of staurosporine on N-glycosylation and cell adhesion to fibronectin of SW480 human colorectal adenocarcinoma cells.
     Eur J Pharm Sci, 25(2): 221-7. [Abstract] [Full-text]
145. The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment.
     Cancer Lett, 224(1): 111-6. [Abstract] [Full-text]
146. Equivocal impact of transplacental and lactational exposure to a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, on prostate and colon lesion development in F344 rats.
     Cancer Lett, 224(1): 23-30. [Abstract] [Full-text]
147. Prognostic significance of lymphovascular invasion in surgically cured rectal carcinoma.
     Am J Surg, 189(6): 707-13. [Abstract] [Full-text]
148. Perioperative hypothermia does not enhance the risk of cancer dissemination.
     Am J Surg, 189(6): 651-5. [Abstract] [Full-text]
149. Information needs of specialist healthcare professionals: a preliminary study based on the West of Scotland Colorectal Cancer Managed Clinical Network.
     Health Info Libr J, 22(2): 133-42. [Abstract] [Full-text]
150. The significance and clinical factors associated with a subcentimeter resection of colorectal liver metastases.
     Ann Surg Oncol, 12(5): 374-80. [Abstract] [Full-text]
151. MS-920: DNA repair gene polymorphisms, diet and colorectal cancer risk in Taiwan.
     Cancer Lett, 224(2): 279-88. [Abstract] [Full-text]
152. Computer-aided detection (CAD) for CT colonography: a tool to address a growing need.
     Br J Radiol, 78: S57-62. [Abstract] [Full-text]
153. Statins and the risk of colorectal cancer.
     N Engl J Med, 352(21): 2184-92. [Abstract] [Full-text]
154. Predictors of fecal occult blood test (FOBT) completion among low-income adults.
     Prev Med, 41(2): 676-84. [Abstract] [Full-text]
155. Colorectal cancer screening: physician recommendation is influential advice to Marylanders.
     Prev Med, 41(2): 367-79. [Abstract] [Full-text]
156. Setting educational priorities for women's preventive health: measuring beliefs about screening across disease states.
     J Womens Health (Larchmt), 14(4): 324-30. [Abstract] [Full-text]
157. Raloxifene and colorectal cancer.
     J Womens Health (Larchmt), 14(4): 299-305. [Abstract] [Full-text]
158. Cancer screening beliefs and reactions to an innovative colorectal cancer screening kit among Chinese worksite population.
     Methods Inf Med, 44(2): 315-8. [Abstract] [Full-text]
159. Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
     J Clin Oncol, 23(16): 3802-10. [Abstract] [Full-text]
160. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study.
     J Clin Oncol, 23(16): 3713-7. [Abstract] [Full-text]
161. A data management approach to quality assurance using colorectal carcinoma reports from two institutions as a model.
     Am J Clin Pathol, 124(1): 83-8. [Abstract] [Full-text]
162. Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms.
     Am J Clin Pathol, 124(1): 11-9. [Abstract] [Full-text]
163. Epidermal growth factor receptor expression in anal canal carcinoma.
     Am J Clin Pathol, 124(1): 20-3. [Abstract] [Full-text]
164. Doppler perfusion index fails to predict the presence of occult hepatic colorectal metastases.
     Eur J Surg Oncol, 31(5): 521-7. [Abstract] [Full-text]
165. Cancer cell dissemination during curative surgery for colorectal liver metastases.
     Eur J Surg Oncol, 31(5): 506-11. [Abstract] [Full-text]
166. Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal cancer.
     Cancer Lett, 225(1): 99-103. [Abstract] [Full-text]
167. Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.
     Cancer Lett, 225(1): 61-74. [Abstract] [Full-text]
168. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service.
     J Am Coll Surg, 200(6): 876-82; discussion 882-4. [Abstract] [Full-text]
169. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
     J Am Coll Surg, 200(6): 845-53. [Abstract] [Full-text]
170. Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients.
     Eur J Surg Oncol, 31(5): 512-20. [Abstract] [Full-text]
171. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
     J Clin Oncol, 23(16): 3706-12. [Abstract] [Full-text]
172. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
     Int J Cancer, 116(2): 322-6. [Abstract] [Full-text]
173. Melatonin potentiates flavone-induced apoptosis in human colon cancer cells by increasing the level of glycolytic end products.
     Int J Cancer, 116(2): 236-42. [Abstract] [Full-text]
174. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.
     Int J Cancer, 116(2): 275-81. [Abstract] [Full-text]
175. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
     Int J Cancer, 116(2): 304-13. [Abstract] [Full-text]
176. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
     J Clin Oncol, 23(16): 3697-705. [Abstract] [Full-text]
177. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites.
     Med Clin North Am, 89(4): 771-93. [Abstract] [Full-text]
178. Mechanisms of mitochondrial apoptosis induced by peripheral benzodiazepine receptor ligands in human colorectal cancer cells.
     Biochem Biophys Res Commun, 332(3): 646-52. [Abstract] [Full-text]
179. Discrete-choice experiment to measure patient preferences for the surgical management of colorectal cancer.
     Br J Surg, 92(6): 742-7. [Abstract] [Full-text]
180. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer.
     Br J Surg, 92(6): 756-63. [Abstract] [Full-text]

© 2004-2010 Colorectal Cancer Research Today. All Rights Reserved.